Cargando…
Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model
Glioblastoma (GBM), WHO grade IV, is the most aggressive primary brain tumor in adults. The median survival time using standard therapy is only 12–15 months with a 5-year survival rate of around 5%. Thus, new and effective treatment modalities are of significant importance. Signal transducer and act...
Autores principales: | Linder, Benedikt, Weirauch, Ulrike, Ewe, Alexander, Uhmann, Anja, Seifert, Volker, Mittelbronn, Michel, Harter, Patrick N., Aigner, Achim, Kögel, Donat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468565/ https://www.ncbi.nlm.nih.gov/pubmed/30857197 http://dx.doi.org/10.3390/cancers11030333 |
Ejemplares similares
-
STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death
por: Remy, Janina, et al.
Publicado: (2022) -
The Role of the Helper Lipid on the DNA Transfection Efficiency of Lipopolyplex Formulations
por: Du, Zixiu, et al.
Publicado: (2014) -
Multicompartmental Lipopolyplex as Vehicle for Antigens and Genes Delivery in Vaccine Formulations
por: Sanmartín, Isaías, et al.
Publicado: (2021) -
Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner()()
por: Kiprianova, Irina, et al.
Publicado: (2015) -
Therapeutic miR-506-3p Replacement in Pancreatic Carcinoma Leads to Multiple Effects including Autophagy, Apoptosis, Senescence, and Mitochondrial Alterations In Vitro and In Vivo
por: Borchardt, Hannes, et al.
Publicado: (2022)